CD19 and acute lymphoblastic leukemia: CD19-targeted CAR-T monotherapy has limited ability to overcome these two core resistance mechanisms, and achieving long-term durable remission remains a critical unmet clinical need in adults with high-risk, chemorefractory B-ALL.<h4>Methods</h4>This is a single-center, retrospective case report of an adult patient with early-relapsed, chemorefractory B-ALL.